Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia - Wikidata - wikimedia - TriplyDB

Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia

Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia

http://www.wikidata.org/entity/Q30425903

about

Epigenetic regulators and their impact on therapy in acute myeloid leukemia Modulation of Protein-Protein Interactions for the Development of Novel Therapeutics Recent progress toward epigenetic therapies: the example of mixed lineage leukemia Features of protein-protein interactions that translate into potent inhibitors: topology, surface area and affinity Hijacked in cancer: the KMT2 (MLL) family of methyltransferases Structural insights into inhibition of the bivalent menin-MLL interaction by small molecules in leukemia.High-Affinity Small-Molecule Inhibitors of the Menin-Mixed Lineage Leukemia (MLL) Interaction Closely Mimic a Natural Protein–Protein Interaction Property Focused Structure-Based Optimization of Small Molecule Inhibitors of the Protein-Protein Interaction between Menin and Mixed Lineage Leukemia (MLL)Multiple endocrine neoplasia type 1 (MEN1) and type 4 (MEN4)A RUNX2-Mediated Epigenetic Regulation of the Survival of p53 Defective Cancer Cells Menin determines K-RAS proliferative outputs in endocrine cells Disordered epigenetic regulation in MLL-related leukemia.The role of HTS in drug discovery at the University of Michigan.Hemoglobin switching's surprise: the versatile transcription factor BCL11A is a master repressor of fetal hemoglobin.Chromatin modifications as therapeutic targets in MLL-rearranged leukemia.Requirement for CDK6 in MLL-rearranged acute myeloid leukemia.The molecular mechanics of mixed lineage leukemia.Targeting Epigenetic Pathways in the Treatment of Pediatric Diffuse (High Grade) Gliomas.The same site on the integrase-binding domain of lens epithelium-derived growth factor is a therapeutic target for MLL leukemia and HIV.Two decades of leukemia oncoprotein epistasis: the MLL1 paradigm for epigenetic deregulation in leukemia.Challenges and opportunities in targeting the menin-MLL interaction.Unravelling the genomic targets of small molecules using high-throughput sequencing.Pharmacologic inhibition of the Menin-MLL interaction blocks progression of MLL leukemia in vivo.Targeting protein-protein interactions in hematologic malignancies: still a challenge or a great opportunity for future therapies?State-of-the-art strategies for targeting protein-protein interactions by small-molecule inhibitors.Successful strategies in the discovery of small-molecule epigenetic modulators with anticancer potential.Design of a fluorescent ligand targeting the S-adenosylmethionine binding site of the histone methyltransferase MLL1.Disrupted intricacy of histone H3K4 methylation in neurodevelopmental disorders.Small molecule screen for inhibitors of expression from canonical CREB response element-containing promoters Gain-of-function p53 mutants co-opt chromatin pathways to drive cancer growth.Chemical methods to induce Beta-cell proliferation.Rational Design of Orthogonal Multipolar Interactions with Fluorine in Protein-Ligand Complexes Cell-Cycle Control of Bivalent Epigenetic Domains Regulates the Exit from Pluripotency Recurrent FGFR3-TACC3 fusion gene in nasopharyngeal carcinoma Histone H2B ubiquitin ligase RNF20 is required for MLL-rearranged leukemia.Menin-MLL inhibitors block oncogenic transformation by MLL-fusion proteins in a fusion partner-independent manner.MLL1 and MLL1 fusion proteins have distinct functions in regulating leukemic transcription program Targeted drug discovery for pediatric leukemia.An MLL-dependent network sustains hematopoiesis.Distinct pathways regulated by menin and by MLL1 in hematopoietic stem cells and developing B cells.

P2860

Q26765402-0AF33F4F-C5EC-4580-8F35-6AF0DC957C6F Q26775356-E09A8C9E-BC92-4AAE-8D02-666B5518EE44 Q26863577-5E02AC97-2BBA-42F0-94E6-FF97013AA2E3 Q26996645-C0EC23A3-06F9-4A38-80CC-D48288A130AD Q27006839-F950F017-3B58-45E1-9743-7277BD4D8DA0 Q27671806-E8EFD339-3E2B-41AA-93F9-6BF3087AE010 Q27681486-BAEB60E3-CB38-4BF7-8047-EF82B33DC5F4 Q27703522-81E62DB1-3F0D-42F6-AB48-67E58D8EAB8E Q28296266-904A542A-86DD-4FF4-9CFC-CA083CB06AA7 Q28550430-E5FCCB68-DA9E-4335-A18A-78DED37C18FD Q28589291-ACBF9E57-15D2-40F7-A84F-EC31E30DA6E7 Q30422159-A102159A-E157-4F4F-A2E8-C2FD3E51D24C Q31147980-D3DC6899-F3FD-49EE-83A7-B6889F4FC607 Q33361527-93BCA1B3-303D-4823-98F3-C889C43BD489 Q33666543-CED94BF0-25C1-4561-AF27-4BA1195C1278 Q34310186-2DB15371-459F-46F3-B761-6FB7DD55BFD3 Q34516051-F34F7B7F-A84E-4161-9D2D-842D8BF41B9D Q34552042-7C4F94A0-C3C8-45ED-A9A0-27A7BE2D56BA Q34683981-CF6B0969-A14C-4E5B-99B3-3F6B0B4B9D78 Q35018755-406CA887-DADC-4B0C-ACEA-7AD6C8E047BA Q35122366-9C1CD152-1D3A-4D20-BF94-54DD72939E10 Q35328171-F832EF3B-4972-4966-A82E-61EAFFB45882 Q35557914-25336203-718E-4A7A-87B4-DDCD17E1C773 Q35687836-A9B29616-6AD1-4680-96FF-E26643468463 Q35738960-868DAE90-1C6A-4282-92FB-F2240CC957F0 Q35824823-FB69A4B8-58DD-4231-BB16-B7ECF05E499D Q35833904-EA36A58E-22CC-4FEE-9534-6A3804D208FE Q35849485-5D11DF77-6470-4A59-9B6A-D134F7FD0C39 Q35912981-B059766C-4C7F-4E71-9399-21608552EA30 Q36056465-6B530BB5-FCBB-4FD7-9E2F-7CD9D5E2DFFE Q36090704-6C344E2D-ED9C-49C7-8594-420072DD6C80 Q36096683-970560E7-D111-44A7-A5D3-83FA17C3D72C Q36200995-F70B8164-A25C-4BA0-A77C-D9E63BA6F434 Q36211300-C28429BF-F10F-4170-9A4D-A1481F7C375D Q36673042-45C14CDE-BDEC-41A8-84F8-985BED1F3AA0 Q36795534-F2F8BFF7-1E90-4BAD-A427-7970E541BFC3 Q36906949-214F95FD-C714-411B-82D3-F155B274B0CD Q36989223-DC838A66-C5D9-43D7-85D3-407D62B49FFA Q37031831-F385762D-4CC1-45F9-80DE-94B713A92F09 Q37186452-77A7C298-37AB-41CF-B4E5-5CA203DAE9B6

P2860

Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia

http://www.wikidata.org/entity/Q30425903

description

2012 nî lūn-bûn

@nan

2012 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

name

Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia

@ast

Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia

@en

type

label

Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia

@ast

Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia

@en

prefLabel

Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia

@ast

Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia

@en

P1433

Q30425903-E8AEB7E8-3DAF-4891-B2E9-901C19C27026

P1476

Q30425903-D177727D-B8BA-420F-B9BD-7D738F4D7E7F

P2093

Q30425903-1D6E5646-F6DA-431B-83DA-4E559502B134

Q30425903-2CC76C3F-5253-442E-A792-724EA7AD1985

Q30425903-3138B9F3-E5E6-4B9E-9F8D-6C1C236F8CD6

Q30425903-43402F3E-0E01-4B40-97D0-EBF46AE22155

Q30425903-5739A6A8-F217-4C01-BF5E-9763C67B1A37

Q30425903-5D5BF92D-9E63-464E-A8B3-16970E395E3F

Q30425903-97F62861-F8CC-4F5D-ACF9-774AEF790106

Q30425903-A3586441-37FE-442B-8D2B-D7772E833EA7

Q30425903-B263E6BC-5E14-45B6-8D38-9F292FC4DA40

Q30425903-D7E38526-A588-4223-B9E6-F6C072332E59

P2860

Q30425903-0048D753-826B-49CE-855D-E1A6DCC4FC10

Q30425903-0167D192-CE48-41F0-A520-8257CF3222AD

Q30425903-09DDE7EA-AA93-45E7-BCCE-EBFB42622D8B

Q30425903-0AADC8D6-1BC6-4862-8978-8DB0D81DD3DA

Q30425903-0B5B985C-EFC2-4726-B365-7026CACEA5E8

Q30425903-0C4A901A-EDA7-455E-9174-193DAA8A25F8

Q30425903-0D5CE04D-D341-4BC1-B2A5-8397CDD78838

Q30425903-14D472E9-7CAA-405B-8864-D0730E24D0D2

Q30425903-1BE384E4-B817-41B0-AC43-B93D7F492039

Q30425903-1E308148-BC52-4978-9F24-0BA30BF4BE9D

P2888

Q30425903-06F56BD6-A9D1-460C-A7BE-A7C78FF0ABC6

P304

Q30425903-43DDB93A-AE69-464C-9B9A-21912DE3E4C0

P31

Q30425903-7C4F4EC0-D302-4947-95DF-BDC4D4DD31E0

P356

Q30425903-349821F9-89B0-4216-B020-B120DC01E39B

P433

Q30425903-DD0BE9E9-8B22-427F-9B69-DA456393B798

P478

Q30425903-1C19590A-5987-4DEB-976D-BE4BEE269911

P50

Q30425903-988B937C-2451-4488-B3E5-E41B606EA22A

P577

Q30425903-63AF5A5C-0C0D-48EC-A7CA-F39AEDBF7014

P5875

Q30425903-508B8E3E-4C4F-4A74-95E6-847770C19F94

P698

Q30425903-BB2A9C7D-DB5B-480F-AF5D-6F86AF7B2679

P921

Q30425903-E526F5F5-DD0A-488F-9486-D0E23E3A5E27

P932

Q30425903-FF31082A-3E5D-4309-95BC-73260499DE0B

P356

P1433

Nature Chemical Biology

P1476

Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia

@en

P2093

Aibin Shi

http://www.w3.org/2001/XMLSchema#string

Amalia M Belcher

http://www.w3.org/2001/XMLSchema#string

Andrew G Muntean

http://www.w3.org/2001/XMLSchema#string

Jay L Hess

http://www.w3.org/2001/XMLSchema#string

Jolanta Grembecka

http://www.w3.org/2001/XMLSchema#string

Marcelo J Murai

http://www.w3.org/2001/XMLSchema#string

Roderick J Sorenson

http://www.w3.org/2001/XMLSchema#string

Shihan He

http://www.w3.org/2001/XMLSchema#string

Thomas Hartley

http://www.w3.org/2001/XMLSchema#string

Tomasz Cierpicki

http://www.w3.org/2001/XMLSchema#string

P2860

Leukemia proto-oncoprotein MLL forms a SET1-like histone methyltransferase complex with menin to regulate Hox gene expression

A higher-order complex containing AF4 and ENL family proteins with P-TEFb facilitates oncogenic and physiologic MLL-dependent transcription

Menin associates with a trithorax family histone methyltransferase complex and with the hoxc8 locus

The PAF complex synergizes with MLL fusion proteins at HOX loci to promote leukemogenesis

Menin and MLL cooperatively regulate expression of cyclin-dependent kinase inhibitors

The tumor suppressor menin regulates hematopoiesis and myeloid transformation by influencing Hox gene expression.

Hoxa9 and Meis1 are key targets for MLL-ENL-mediated cellular immortalization

Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays

Crystal structure of menin reveals binding site for mixed lineage leukemia (MLL) protein

Molecular classification of cancer: class discovery and class prediction by gene expression monitoring

P2888

P304

277-284

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NCHEMBIO.773

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

Hollis D Showalter

P577

2012-01-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221785705

http://www.w3.org/2001/XMLSchema#string

P698

22286128

http://www.w3.org/2001/XMLSchema#string

P921

P932

3401603

http://www.w3.org/2001/XMLSchema#string